Finance

Lists
DUL:ETR
Alnylam Pharmaceuticals, Inc.
205,50 €
-0,48%
(-1,00) 1D
12 ოქტ, 17:35:58 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for DUL...
Open
209,10 €
High
209,10 €
Low
205,50 €
Mkt. cap
30,38 მლრდ.
Avg. vol.
40,00
Volume
10,00
52-wk high
417,40 €
52-wk low
177,10 €
No. of employees
2 ათ.
Open
209,10 €
High
209,10 €
Low
205,50 €
Mkt. cap
30,38 მლრდ.
Avg. vol.
40,00
Volume
10,00
52-wk high
417,40 €
52-wk low
177,10 €
No. of employees
2 ათ.
News stories
From web sources and news partners
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEO-
Employees2,5 ათ.
Founded14 ივნ. 2002
Headquarters-
Sector-
Websitealnylam.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,25 მლრდ.
1,10 მლრდ.
1,17 მლრდ.
1,29 მლრდ.
Cost of goods sold
200,15 მლნ.
267,72 მლნ.
211,12 მლნ.
298,45 მლნ.
Cost of revenue
200,15 მლნ.
267,72 მლნ.
211,12 მლნ.
298,45 მლნ.
Research and development expenses
358,81 მლნ.
372,22 მლნ.
364,87 მლნ.
413,13 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
322,08 მლნ.
325,37 მლნ.
322,55 მლნ.
347,92 მლნ.
Operating expense
680,89 მლნ.
697,59 მლნ.
687,42 მლნ.
761,06 მლნ.
Total operating expenses
881,04 მლნ.
965,32 მლნ.
898,54 მლნ.
1,06 მლრდ.
Operating income
367,98 მლნ.
131,72 მლნ.
268,64 მლნ.
231,44 მლნ.
Other non operating income
-74,15 მლნ.
92,98 მლნ.
-4,30 მლნ.
273,00 ათ.
EBT including unusual items
238,97 მლნ.
161,14 მლნ.
221,65 მლნ.
177,81 მლნ.
EBT excluding unusual items
278,12 მლნ.
121,99 მლნ.
221,65 მლნ.
177,81 მლნ.
Income tax expense
-12,12 მლნ.
-25,28 მლნ.
15,66 მლნ.
13,31 მლნ.
Effective tax rate
-5,07%
-15,69%
7,07%
7,49%
Other operating expenses
-
-
-
-
Net income
251,08 მლნ.
186,42 მლნ.
205,99 მლნ.
164,49 მლნ.
Net profit margin
20,10%
16,99%
17,65%
12,74%
Earnings per share
2,90
1,25
1,99
1,84
Interest and investment income
28,68 მლნ.
26,63 მლნ.
26,60 მლნ.
28,14 მლნ.
Interest expense
-44,40 მლნ.
-129,34 მლნ.
-69,29 მლნ.
-82,05 მლნ.
Net interest expenses
-15,72 მლნ.
-102,71 მლნ.
-42,69 მლნ.
-53,91 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
381,78 მლნ.
145,22 მლნ.
282,19 მლნ.
245,34 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები